english.prescrire.org > Topics > Advancing healthcare policy > Methotrexate: room for improvement in packaging and patient information (5/2018)
Advancing healthcare policy

Via its policy advocacy, Prescrire acts as a force for change in health policies, first and foremost in the interest of patients.

Français

Methotrexate: room for improvement in packaging and patient information (May 2018)

Prescrire took part in the informal consultation undertaken by the Pharmacovigilance and Risk Assessment Committee (PRAC, the EMA’s medicines safety body), regarding medication errors due to daily instead of weekly administration of methotrexate in non-oncologic indications, and evaluating the effectiveness of risk minimisation measures intended to prevent such errors. Prescrire urges that several root causes which are within the remit of the European Medicines Agency, such as regulation, packaging, labelling and medication safety awareness, not be overlooked. Read on...
 

Paris, 29 May 2018

Summary

Prescrire took part in the informal consultation undertaken by the Pharmacovigilance and Risk Assessment Committee (PRAC, the EMA’s medicines safety body), regarding medication errors due to daily instead of weekly administration of methotrexate in non-oncologic indications, and evaluating the effectiveness of risk minimisation measures intended to prevent such errors. Prescrire urges that several root causes which are within the remit of the European Medicines Agency, such as regulation, packaging, labelling and medication safety awareness, not be overlooked.

©Prescrire 2018

> Download Prescrire's response to the PRAC consultation (pdf, 144 Ko)

Share Share on Facebook Share on Twitter